Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorecivivint in symptomatic knee osteoarthritis
NCT03706521Phase 2Terminated
- Sponsor
- Biosplice Therapeutics
- Start
- Mar 2019
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lorecivivint in knee osteoarthritis (OA), sponsored by Biosplice Therapeutics. Primary endpoints: Change From Baseline in Medial Tibial Cartilage Thickness at 26 weeks, Change From Baseline in Medial Tibial Cartilage Volume at 26 weeks and 2 more. Started Mar 2019; status: terminated.
02
Drugs
lorecivivint
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT03706521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03706521.